Drug Research
Drug Discovery & Development

Compugen expands operations to California

PBR Staff Writer Published 29 March 2012

Israel based Compugen Ltd. has established operations in South San Francisco, California, US, for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets.

The goal of Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company into promising mAb drug candidates for licensing and partnering.

With the new South San Francisco operations, the company anticipates that it will increase the number of mAb product candidates developed against novel Compugen-discovered targets.

Mary Haak-Frendscho will join as executive chairperson of Compugen Inc., and John J. Hunter, as its vice president of Antibody R&D and site head, effective 1 April, announced Compugen Ltd.

The mAb Targets Discovery Platform utilizes multiple data sources and algorithms to predict a number of novel membrane proteins that can serve as targets for antibody therapeutics.